報價延遲最少15分鐘:2025/04/29 15:00 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3433 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-13.83/-16.50
|
|
企業價值
4.12M
|
| 資產負債 |
|
每股賬面淨值
-0.02
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
8.01M
|
|
每股收益
0.93
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/29 15:00 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States. |